Ignite Creation Date:
2024-05-05 @ 12:07 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259363
Status:
TERMINATED
Last Update Posted:
2009-12-07
First Post:
2005-11-28
Brief Title:
Oxaliplatin in Rectal Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Phase I-II Study of Preoperative Oxaliplatin-FU and Radiotherapy for Patients With Rectal Cancer
Status:
TERMINATED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study cancelled because recruitment rate was too slow
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I To determine the maximum tolerated dose and recommended dose of the proposed doses of oxaliplatin in this study
Phase II To determine the treatment efficacy according to response rates from phase I
Phase II To determine the treatment efficacy according to response rates from phase I
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None